<DOC>
	<DOCNO>NCT00042315</DOCNO>
	<brief_summary>To determine whether tariquidar + first-line single agent vinorelbine chemotherapy patient Stage IIIb/IV NSCLC , acceptable safety profile , significantly improve overall survival compare placebo + vinorelbine . To compare effect tariquidar/vinorelbine placebo/vinorelbine tumor response , time disease progression , performance status , symptom progression , quality life patient Stage IIIb/IV NSCLC .</brief_summary>
	<brief_title>A Double-Blind , Randomized , Placebo-Controlled , Multicenter , Phase III Study Tariquidar + Vinorelbine First-Line Therapy Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>1 . Patients histologically cytologically proven NSCLC , stage IIIb stage IV , require firstline chemotherapy . 2 . Patients WHO performance status 2 life expectancy great 3 month . 3 . Patients 18 year age old age consent . 4 . Patients woman childbearing potential must pregnant lactating , must negative pregnancy test ( serum urine ) screening , must practice adequate method birth control . 5 . Patients neutrophils great equal 1.5 x 103/µL ; platelet great equal 100 x 103/µL ; bilirubin le equal 1.5 time upper limit normal less equal 26 µmol/L ( 1.5 mg/dL ) ; transaminases less equal 2.5 time upper limit normal , patient know liver metastasis , less equal 5 time upper limit normal ; creatinine equal less 141 µmol/L ( 1.6 mg/dL ) calculate creatinine clearance less equal 60 mL/min prior study treatment . 6 . Patients able give write informed consent comply protocol . 1 . Patients eligible radiotherapy surgery curative intent . 2 . Patients previous chemotherapy NSCLC . 3 . Patients WHO performance status le 2 great 2 . 4 . Patients bronchoalveolar carcinoma ( adenocarcinoma cylindrical tumor cell grow upon wall preexist alveolus , WHO histological type lung tumor [ 66 ] ) . 5 . Patients previous current primary malignancy sit within last 5 year , exception adequately treat conebiopsied carcinoma cervix basal squamous cell skin carcinoma . 6 . Patients poor medical risk nonmalignant systemic disease active uncontrolled infection . 7 . Patients symptomatic brain metastasis . 8 . Patients medical surgical condition would contraindicate chemotherapy . 9 . Patients receive experimental therapy within last 4 week . 10 . Patients know hypervitaminosis know sensitivity ascorbic acid , vitamin A , vitamin D , thiamine , riboflavin , pyridoxine , niacinamide , dpanthenol , vitamin E .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>